The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
TBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts) with HER2+ metastatic breast cancer (MBC).
N. U. Lin
Consultant or Advisory Role - Genentech (U); GlaxoSmithKline; Infinity (U); Johnson & Johnson
Research Funding - Boehringer Ingelheim; Genentech; GlaxoSmithKline; Infinity
I. A. Mayer
No relevant relationships to disclose
J. S. Najita
No relevant relationships to disclose
T. J. Hobday
No relevant relationships to disclose
C. I. Falkson
Consultant or Advisory Role - Genentech
Honoraria - Genentech
E. C. Dees
Research Funding - Genentech; GlaxoSmithKline
M. F. Rimawi
Research Funding - GlaxoSmithKline
R. Nanda
Research Funding - Roche
R. S. Gelman
No relevant relationships to disclose
K. Josephs
No relevant relationships to disclose
A. Richardson
Consultant or Advisory Role - Genentech
L. Flores
No relevant relationships to disclose
A. D. Van Den Abbeele
Consultant or Advisory Role - Bristol-Myers Squibb (U)
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline
J. T. Yap
Research Funding - GlaxoSmithKline
C. L. Arteaga
No relevant relationships to disclose
A. C. Wolff
Research Funding - Genentech
I. E. Krop
Consultant or Advisory Role - Genentech (U)
Research Funding - Genentech
E. P. Winer
No relevant relationships to disclose